All In Biotech

Drug Trial Radar · NCT05610189

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

A Phase 1, Randomized, Multiple-dose, Crossover Trial in Participants With Parkinson's Disease to Evaluate the Clinical Bioequivalence Between Tavapadon Tablets

Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Dec 15, 2022

Primary completion

Dec 12, 2023

Study completion Dec 17, 2023

Sponsor

Lead sponsor
Cerevel Therapeutics, LLCIndustry
Sponsor type
Industry
First posted
Nov 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

  • TavapadonDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax) of TavapadonTime frame: Pre-dose and at multiple timepoints post-dose up to Day 28
  2. Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of TavapadonTime frame: Pre-dose and at multiple timepoints post-dose up to Day 28

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Los Alamitos, California

    Los Alamitos, California

  • Hollywood, Florida

    Hollywood, Florida

  • Orlando, Florida

    Orlando, Florida

  • South Miami, Florida

    South Miami, Florida

  • Decatur, Georgia

    Decatur, Georgia

  • Farmington Hills, Michigan

    Farmington Hills, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.